COL-3 new tetracycline derivative being studied

Written by on August 11, 2005 in tetracyclines with 0 Comments

A new anti-inflammatory compound has had some Phase 2 Clinical information published. COL-3 is a so called second generation IMPACS (Inhibitors of Multiple Proteases and Cytokines) compound. It is a tetracycline derivate, and is also designated as a Synthetic MMP (Matrix Metalloproteinsase) inhibitor.

Guy Webster, MD. PhD the lead investigator for these Phase 2 clinical trials of COL-3 says

“This is the first double-blinded, placebo-controlled clinical study evaluating COL-3’s therapeutic potential. The magnitude of the effect was greater than anticipated and the onset of action much faster, making COL-3 a promising candidate for development.”

COL-3 is being developed by Collagenex Pharmaceuticals who is also developing Oracea, another antibiotic variant targetted as a rosacea treatment.

According to Collagenex, research has shown that certain tetracyclines can be chemically modified to retain non-antibiotic properties that may make them effective in treating diseases involving inflammation and/or destruction of the body’s connective tissues.

COL-3 is also undergoing Phase I trials as an angiogenesis inhibitor.

Related Articles:

Read more about: tetracyclines

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed

Leave your comment here


Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.